ProKidney Corp - Class A

PROK | $1.82 0.0% 410K

(0.0% 1d) (0.3% 1m) (-84.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-69.19% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 422,720,829

Sec Filling | Patents | 4 employees

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.

t-cell

add to watch list email alert is off

Press-releases

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
Published: 2023-11-30 (Crawled : 13:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| -11.58% | O: -1.58% H: 2.14% C: -10.16%
MS | News | $80.35 1.18% -0.03% 5.3M

Finance

| 2.41% | O: 0.28% H: 0.9% C: 0.72%
business

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
Published: 2023-11-21 (Crawled : 11:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| 30.23% | O: 39.53% H: 20.28% C: 3.33%
conference

ProKidney Reports Third Quarter Financial Results
Published: 2023-11-14 (Crawled : 11:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| 6.33% | O: 17.41% H: 0.0% C: 0.0%
financial results

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| 6.33% | O: 17.41% H: 0.0% C: 0.0%
rmcl-002 react renal positive cell trial therapy diabetic

ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
Published: 2023-10-30 (Crawled : 20:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| Email alert Add to watchlist
kidney presentation week

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
Published: 2023-09-05 (Crawled : 10:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| -80.05% | O: 1.9% H: 0.0% C: 0.0%
MS | News | $80.35 1.18% -0.03% 5.3M

Finance

| -6.29% | O: 0.01% H: 0.0% C: 0.0%
conference global

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| Email alert Add to watchlist
financial results

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
Published: 2023-07-18 (Crawled : 10:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| -85.83% | O: 0.34% H: 2.77% C: -4.29%

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
Published: 2023-07-17 (Crawled : 10:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| -84.89% | O: 0.36% H: 8.87% C: 6.27%
commercialization

ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
Published: 2023-06-13 (Crawled : 16:00) - globenewswire.com
PROK | $1.82 0.0% 410K

| -85.83% | O: -1.52% H: 5.99% C: -0.17%

See all